濮阳东方医院妇科做人流价格非常低濮阳东方医院妇科收费低吗,濮阳东方医院看男科病非常可靠,濮阳东方妇科收费不贵,濮阳东方医院看早泄好不,濮阳东方医院治早泄口碑好价格低,濮阳东方医院看早泄可靠,濮阳东方医院男科看阳痿价格收费低

ABU DHABI, Feb. 10 (Xinhua) -- China is willing to deepen friendship, broaden cooperation, and enhance coordination with the United Arab Emirates (UAE) in international and regional affairs, visiting Chinese Foreign Minister Yang Jiechi said Thursday.During a meeting with Abu Dhabi Crown Prince Sheikh Mohammed bin Zayed Al Nahyan, Yang said China and the UAE have witnessed in recent years rapid development in their bilateral ties, with closer high-level contacts, increasingly strengthened mutual political trust, fruitful cooperation in such areas as trade and economy, and broadened cultural exchanges.China has praised the UAE's support in Xinjiang-related and human rights issues, he added.For his part, Sheikh Mohammed said the UAE-China relations are currently at an important period of in-depth development and faced with good opportunities.The UAE attaches great importance to its relations with China and hopes to cement the traditional friendship between the two countries and develop pragmatic cooperation in various fields, he added.Sheikh Mohammed said the UAE expects that China will continue to play a positive role in international and regional affairs.Earlier in the day, Yang also met with his UAE counterpart Sheikh Abdullah bin Zayed Al Nahyan. Both sides reached broad consensus after exchanging views on bilateral ties and regional issues of common concern.The Chinese foreign minister arrived in the UAE capital of Abu Dhabi late Wednesday for an official visit to the Gulf nation.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

BEIJING, Feb. 11 (Xinhua) -- China's foreign exchange regulator said Friday it did not suffer any losses from its investment in Fannie Mae and Freddie Mac bonds, adding that media reports of up to 450 billion U.S. dollars of losses were "groundless.""Up until now, the capital and interest repayments of Fannie Mae and Freddie Mac bonds is normal, and no losses have incurred," The State Administration of Foreign Exchange (SAFE) said on its website.Annual yields of the bonds were around 6 percent between 2008 and 2010, the SAFE said.The regulator, which oversees China's more than 2 trillion U.S. dollars of foreign exchange reserve, also clarifies it had not bought any stocks of the two troubled mortgage companies.UPI reported on Friday that the Obama Administration will propose phasing out the two mortgage giants after rescuing them, which is part of a U.S. Treasury Department white paper to Congress that lays out three ways of cutting government support to the 10.6 trillion U.S. dollars mortgage market.

COPENHAGEN, April 30 (Xinhua) -- As traditional Chinese medicine (known as TCM in Europe) becomes increasingly popular worldwide and has gradually been regarded as a useful component to Western medical treatments, Denmark is no stranger to such trends.According to a study published by the University of Copenhagen in mid-Feb., up to one-third of Danish hospitals choose complementary or alternative therapies, including TCM methods, to treat pain, cancer, mental disease, tumors and infertility. Acupuncture remains the most widely-practiced form of these treatments, used in some 97 percent of the cases.The nationwide acceptance of acupuncture and massage therapists, the growing ranks of herbal practitioners, and the hosting of an annual pan-Scandinavian TCM conference since 2007, all underline the popularity of alternative medicine, including the TCM, in the country.However, the overall market presence of TCM, and herbal medicines in particular, is relatively small in Denmark and Europe at large. As many European policymakers insist that traditional herbal medicines "are neither scientifically documented nor tested according to Western requirements," these treatments face difficulties in obtaining licenses and boosting sales in Europe.In fact, despite their historical pedigree and widely-accepted efficacy, TCM products are often classified as "healthcare products" or "food," rather than "drugs" in European markets.A big challenge for TCM products to gain more access to the continent is the EU's Traditional Herbal Medicinal Products Directive, which stipulates that all such products must obtain authorization if they are to be sold within the EU, starting May 1, 2011.The directive says producers must prove the product in question has been used for 30 years, 15 of which within the EU, so as to ensure its safety.While licensing is expected to be onerous and expensive, Denmark has tried to bring TCM products into the Western medical mainstream from as early as 2005. The country's well-developed biochemical and medical industry, modernized agriculture and horticulture sectors and a strong track record of cooperative research in these fields, has helped TCM's cause.For instance, Traditional Complementary Medicine Denmark, a company helping herbal product makers market their goods in Western countries, uses modern biotechnology processes and clinical trials to scientifically verify and document the efficacy of existing herbal medicines.It also advises herbal product makers on how to align their standards with European requirements so as to acquire the necessary sales licenses. Sometimes, simple solutions like clearer and more detailed labeling of a TCM product's ingredients can help improve its marketability. Patent applications and drug approvals procedures must follow, before the product can access the EU pharmaceutical market, usually in pill form.Investing in herbal medicine also makes financial sense for Denmark, as it is encourages development of low-bulk, high-value agricultural products, which can be easily transported all over the globe.Development Centre Aarslev, a Danish agro-research body and partner of TCM Denmark, studies the active ingredients contained in medicinal plants and their impact on human health conditions such as cardiovascular problems, diabetes and allergies. One of the earliest collaborations it undertook with a producer of herbal medicine showed the effectiveness of extracts from the hips of the dog rose plant in treating rheumatoid arthritis.A spokesperson for the institution said, "We have documented analytical evidence which shows that arthritis patients can reduce their consumption of conventional anti-arthritis drugs by up to 50 percent, if they combine them with the herbal drug based on dog rose hips."Given Denmark's population of 5.5 million people, this could translate into savings of 200 million U.S. dollars a year on anti-arthritis medication, the spokesperson added.Other plant-based interventions could hold wider public health benefits. TCM practitioners say herbal medicines can improve blood circulation in humans, and contain naturally-occurring antioxidants which can reduce the risks of heart attacks and better regulate cardiovascular functions. This has potentially wide-ranging benefit for Western societies, where heart disease is a major threat.Heart disease was the most common cause of death in Denmark until 2000, and cardiovascular disease the commonest until 2008, with cancer now ranking the biggest killer.In fact, TCM herbal remedies are also considered a good choice for cancer treatment, as certain plants contain hormone-like substance which can influence hormone-dependent cancers, such as breast and prostate cancer.TCM supporters say the obvious benefit of such an intervention is the avoidance of more commonly-used chemotherapy and radiation treatments which often produce severe side-effects in patients. Relevant herbal therapies can help strengthen cancer patient's immune system, reduce side-effects of chemotherapy and radiation therapy, and alleviate other symptoms of the disease.Given the many potential benefits of TCM, the EU's tightening of rules may appear harsh. Still, TCM is considered a relatively novel approach to medicine in Europe. Moreover, the dominant market share and general clout of the chemical-based, Western pharmaceutical industry also makes it difficult for traditional remedies to stake their claim.

BAODING, Feb. 2, (Xinhua) -- All-out efforts should be made to combat drought for a summer grain harvest, said Chinese President Hu Jintao Wednesday in an inspection tour to north China's Hebei Province."We need to adopt comprehensive measures to ensure supply of capital, technologies, facilities and materials to enable winter wheat to safely grow through the winter," said Hu, when inspecting drought conditions at a wheat field in Xishanbei Township of Baoding City, Hebei.Over the past three months, North China has been hit by severe drought, seriously threatening normal agricultural production.Hu, who is also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, made the inspection visit in Baoding from Tuesday to Wednesday, to welcome the Spring Festival, or China's Lunar New Year, with local officials and residents.Hu beat a drum together with villagers during a new year celebration in Shijiatong Village, Xishanbei Township of Baoding.The president visited the home of Yan Deshu, an aged CPC member in the village, and pasted the Chinese character "Fu", meaning fortune and happiness, on the gate of Yan's yard.Hu also visited a long-distance coach station in Baoding, and extended Spring Festival greetings to passengers, station workers and volunteers.Hu inspected a unit of armed police in Baoding and made Chinese dumplings together with the officers and soldiers.